Differences in MDR1 (C3435T), CYP2D6, and CYP1A2 Genotype Frequencies between Patients with Treatment Failure to Antipsychotics and Healthy Russian Population

  • Zhiganova T
  • Eugenia R
  • Tatiana S
  • et al.
0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Personalized approach is one of the options to overcome treatment failure in psychiatry and increase the efficacy of antipsychotic treatment for an indi-vidual patient by using genetic tests. Objective: The aim of this study was to investigate the frequency of MDR1 (C3435T), CYP2D6, CYP2C19, and CYP1A2 genotypes in psychiatric patients with treatment failure to antipsychotics to compare the results with those published for the Russian popula-tion. Methods: A total number of 52 patients attending a psychiatry outpatient clinic were included in the study. All patients required changing the therapy with antipsychotics due to treatment failure. Results: We revealed the higher frequency of Т/Т MDR1 (C3435T) homozygotes among study patients as compared with the Russian healthy population. For CYP1A2, the higher frequency of normal metabolizers (*1A/*1A) and lower frequency of slow metabolizers (*1F/*1F) were observed. No difference was found for intermediate metabolizers (*1A/*1F) and one patient had *1A/*1C genotype with decreased activity. For the major-ity of CYP2D6 genotypes, the observed frequencies were similar to those reported for the Russian healthy population except for CYP2D6 *3/*4 (slow metabolizers), for which higher frequency among study patients was found. The frequencies of CYP2С19 geno-types were comparable to the Russian population, however, no slow metabolizers (*2/*2, *2/*3, *3/*3 genotypes) were identified. Conclusion: Psychiatric patients with treatment failure to antipsychotics demonstrated a high frequency of T/T MDR1 (C3435T) and CYP2D6 *3/*4 genotypes coding inactive proteins. The frequency of CYP1A2 wild type genotype *A/*A was higher with a simul-taneous decrease in the frequency of *F/*F genotype compared with the healthy Russian population. Further studies of MDR1 (C3435T) genotype as well as CYP2D6, CYP2C19, and CYP1A2 genotypes frequency should be conducted in patients with treatment failure to antipsychotics.

Cite

CITATION STYLE

APA

Zhiganova, T., Eugenia, R., Tatiana, S., & Viktoriia, V. (2020). Differences in MDR1 (C3435T), CYP2D6, and CYP1A2 Genotype Frequencies between Patients with Treatment Failure to Antipsychotics and Healthy Russian Population. Current Pharmacogenomics and Personalized Medicine, 17(1), 55–63. https://doi.org/10.2174/1875692117666190724141831

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free